Evidence map›Paper›PMID 25711194›Full record

ArticleThe Journal of urology2015

Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.

Raj Satkunasivam, Andre E Kim, Mihir Desai, Mike M Nguyen, David I Quinn, Leslie Ballas, Juan Pablo Lewinger, Mariana C Stern, Ann S Hamilton, Monish Aron and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 6 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 6 syntheses or guidelines pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Trial
  8. Review
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Raj SatkunasivamUniversity of Southern California Institute of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California; Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California. Electronic address: raj.satkunasivam@gmail.com.
Andre E KimDepartment of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.
Mihir DesaiUniversity of Southern California Institute of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California; Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.
Mike M NguyenUniversity of Southern California Institute of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California; Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.
David I QuinnDepartment of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California; Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.
Leslie BallasDepartment of Radiation Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California; Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.
Juan Pablo LewingerDepartment of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.
Mariana C SternDepartment of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.
Ann S HamiltonDepartment of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.
Monish AronUniversity of Southern California Institute of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California; Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.
Inderbir S GillUniversity of Southern California Institute of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California; Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.
University of Southern California · US

Funding

Training Grant in Genomic Analysis and InterpretationT32ES013678 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GAUDERMAN, WILLIAM JAMES, MCCONNELL, ROB S · 2006 to 2023
$5.6M
NIEHS NIH HHS 5T32 ES013678NIEHS NIH HHS T32 ES013678
6 · The paper itself

Abstract

purposeWe assessed survival after radical prostatectomy, intensity modulated radiation therapy or conformal radiation therapy vs no local therapy for metastatic prostate cancer adjusting for patient comorbidity, androgen deprivation therapy and other factors. MATERIALS AND

methodsWe identified men 66 years old or older with metastatic prostate cancer treated with radical prostatectomy, intensity modulated radiation therapy, conformal radiation therapy or no local therapy in the SEER-Medicare linked database from 2004 to 2009. Multivariable Cox proportional hazards models before and after inverse propensity score weighting were used to assess all cause and prostate cancer specific mortality. Competing risk regression analysis was done to assess prostate cancer specific mortality.

resultsOf 4,069 men with metastatic prostate cancer radical prostatectomy in 47, intensity modulated radiation therapy in 88 and conformal radiation therapy in 107 were selected as local therapy vs no local therapy in 3,827. Radical prostatectomy was associated with a 52% decrease (HR 0.48, 95% CI 0.27-0.85) in the risk of prostate cancer specific mortality after adjusting for sociodemographics, primary tumor characteristics, comorbidity, androgen deprivation therapy and bone radiation within 6 months of diagnosis. Intensity modulated radiation therapy was associated with a 62% decrease (HR 0.38, 95% CI 0.24-0.61) in the risk of prostate specific cancer specific mortality. Conformal radiation therapy was not associated with improved survival compared to no local therapy. Propensity score weighting yielded comparable results. Competing risk analysis revealed a 42% and 57% decrease (SHR 0.58, 95% CI 0.35-0.95 and SHR 0.43, 95% CI 0.27-0.68, respectively) in the risk of prostate cancer specific mortality for radical prostatectomy and intensity modulated radiation therapy.

conclusionsLocal therapy with radical prostatectomy and intensity modulated radiation therapy but not with conformal radiation therapy was associated with a survival benefit in men with metastatic prostate cancer. This finding warrants prospective evaluation in clinical trials.

Indexed as

MedicareRisk AssessmentSEER ProgramAgedBrachytherapyHumansMaleMiddle AgedPropensity ScoreProportional Hazards ModelsProspective StudiesProstatectomyProstatic NeoplasmsRadiotherapy, ConformalRisk FactorsSurvival Rateintensity-modulatedmortalityprostatectomyprostatic neoplasmsradiotherapySEER program

Identifiers

PMID25711194
PMCPMC4834920
OpenAlexW2105647806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.